Nitric oxide, or NO', is a gas under atmospheric conditions. It is noxious because of its free radical structure. It is biosynthesized from the amino acid L-arginine. 
Introduction
In 1980, a pharmacologist and profound scholar, Robert Furchgott, who had been working solely with a classical organ bath assay for thirty years and never used "modern" techniques such as receptor binding assay or molecular biology, made an epoch-making observation, which attracted the attention of numerous investigators to the endothelium. He discovered that acetylcholine relaxes rabbit aortic smooth muscles only when the endothelium is intact.1 This discovery was not achieved by serendipity.
The story began in 1914 when Sir Henry Dale first observed that intravenous injection of acetylcholine in creased blood flow in the arteries of the rabbit ear and dilated vessels in vivo.2 Investigators attempted to con firm acetylcholine's action in vitro, but without success. The mystery for researchers including Furchgott himself was that the isolated rabbit artery contracted, but did not relax in response to acetylcholine in vitro. In 1962, a paper appeared which described blood vessel relaxation with acetylcholine.3 The author used a new method of preparing rabbit aorta, using a ring preparation in place of helical strip which Furchgott had developed and gained expertise with. Furchgott repeated these experiments and confirmed that acetylcholine relaxes the ring prep aration, but not the helical strip preparation of rabbit aorta. Furchgott identified the source of this apparent contradiction. It turned out that the endothelium had been inadvertently injured during preparation of the helical strip. He demonstrated that acetylcholine-induced relaxation is endothelium-dependent and that even in the ring preparation acetylcholine contracted the rabbit aorta if the endothelium had been removed.1 He reasoned that there must be an unidentified substance, which was released from the endothelium, capable of relaxing the smooth muscles of blood vessels. This obser vation and speculation opened a new era of endothelium research. Now, in 1994 we know that EDRF (endothelium derived relaxing factor) is nitric oxide; NO is enzy matically formed from L-arginine; NO synthase (NOS) has a unique structure in that the enzyme is active with cofactors including FMN, FAD, calmodulin, heme and tetrahydrobiopterin; NOS is broadly divided to consti tutive NOS (cNOS) and inducible NOS (iNOS) forms. The cNOS form is found in endothelial cells, platelets and megakaryoblastic cells, bronchial epithelial cells, the cerebellum, parasympathetic nerves and the macula densa. iNOS is widely distributed in macrophages, vascu lar endothelium and smooth muscles, cardiac myocytes, kidney mesangial cells, chondrocytes, glial cells (astro cytes and microglial cells), and Kupffer cells; NO acti vates guanylate cyclase and stimulates the production of cyclic GMP; the biological activity of NO, however , may not be attributable solely to an increase in cellular cyclic GMP. NO is not merely an object of research curiosity . Nitroglycerin has long been used for the treatment of Reprint The basal release of NO derived from L-arginine plays an important role in regulating blood flow and pressure. Evidence for this comes from the obser vation that, in rabbits, intravenous administration of a specific inhibitor of NO, NG-monomethyl-L-arginine (L-NMMA) induced an increase in blood pressure that was reversible with L-arginine, but not D-arginine.11 The importance of NO in regulating basal tone in resist ance vessels was demonstrated using an NOS inhibitor, L-NMMA, in the isolated coronary circulation.12
The importance of NO in regulating blood flow has also been demonstrated in humans. Studies in which L-NMMA was infused into the human brachial artery or hand dorsal veins demonstrated that vasodilation could be induced by either acetylcholine or bradykinin. Furthermore, whereas in the brachial artery L-NMMA induced direct vasoconstriction, it had no such effect on the hand veins. This observation suggests that on the arterial, but not the venous, side of the circulation there is a continuous release of NO which maintains dilator tone in humans. 13 In the microcirculation, NO plays a role in regulating the vascular tone of arterioles and venules, although there are some variations among tissue preparations.14,15
The physiological stimuli for generation of NO are not yet fully understood, but pulsatile flow and shear stress appear to be two of the main determinants.16 Interest ingly, it was reported that in resistance arteries of the intact rabbit ear, endothelium-dependent vasodilatation in response to acetylcholine was enhanced at increased flow rates.17 Flow-dependent coronary artery dilation has also been demonstrated in humans.18 The three best understood components of hemodynamic force are shear stress, wall tension, and transmural pressure. However, it is difficult to evaluate the effects of transmural pressure alone on vessels in situ. According to the law of Laplace, transmural pressure in a distensible hollow object causes wall tension, which may stretch endothelial cells. In an experimental system where shear stress and stretch can be excluded as much as possible by exposing cells cultured on flat, solid flasks to elevated pressure, we showed that pure pressure inhibits NO formation/release from human umbilical vein endothelial cells.19 A pressure of 80mmHg caused maximal inhibition. Since the mean arterial pressure in healthy humans is in the 80 to 100mmHg range, these results suggest that NO release may be inhibited, to some extent, under physiological conditions. 
Leukocytes
Endogenous NO derived from endothelial cells tonically inhibits the adhesion and aggregation of leuko cytes to endothelium. 25 Inhibitors of NOS lead to in creased expression of CD11/CD18 adhesion molecules on neutrophils, the enhanced CD11/CD18-dependent attachment of the cells to the vessel wall, and their increased emigration into extra vascular tissue.
LPS-induced hepatotoxicity, intestinal tissue damage, and vascular permeability were exacerbated by adminis tration of an NOS inhibitor and ameliorated by ad ministration of S-nitroso-N-acetyl-penicillamine, an NO donor.26,27 In contrast to these findings, however, the same NOS inhibitor administered to the same species blocked immune complex-induced, neutrophil dependent vascular injury in the lung.28
Although endogenous NO appears to exert both pro and antiinflammatory effects, this might be attributable to redox variables affecting the function of NO. The importance of the redox environment will be discussed below, in the section on neuronal death.
Cardiac muscle
Carbachol, a muscarinic agonist, caused 91% in hibition of the spontaneous beating rate of cultured neonatal rat cardiac myocytes. L-NMMA blocked the negative chronotropic effect of carbachol. This inhibitor significantly increased the inotropic effect of the (3-adrenergic agonist isoproterenol on electrically stimu lated adult rat ventricular myocytes. These observations suggest that the physiologic responses of isolated neo natal and adult ventricular myocytes to both muscarinic cholinergic and 3-adrenergic stimulation are mediated, in part, by NO.29
Renin release
Endogenous NO has been shown to inhibit the release of renin.30 In fact, the presence of NOS in the rat macula densa demonstrated by immunoreactivity.31 Tubulo glomerular feedback, which is mediated by the macula densa, appears to be regulated in part by NO. The ability of NO to regulate arteriolar diameter in the kidney may be a key factor in renin release.
Inflammatory stimuli such as cytokines and LPS induce iNOS in mesangial cells.32 This mechanism may play a role in nephritis.
Hypertension
It may be reasonable to speculae as to whether, in hypertensive patients, the vasorelaxing substance NO is reduced in amount. It has been known that basal forearm blood flow is similar in hypertensive patients and con trols. Blood flow and vascular resistance responses to acetylcholine were significantly reduced in hypertensive patients, whereas the response to sodium nitroprusside, an NO donor, was unchanged or enhanced in such patients.33 L-Arginine did not significantly change basal blood flow or vascular resistance in either group. How ever, the infusion of L-arginine significantly augmented the vasodilator response to acetylcholine in normal con trol subjects. In contrast, in hypertensive patients, the infusion of L-arginine did not alter the response to acetylcholine.34 These results suggest that agonist stimulated L-arginine availability is impaired in hyper tensive subjects. However, we have shown that the administration of L-arginine induced a significant re duction in blood pressure in hypertensive, to an extent much greater than that of healthy normal controls.35-37 The blood pressure reduction was accompanied by in creases in the plasma concentrations of cyclic GMP and L-citrulline, the latter being a byproduct of NO formation from L-arginine. Furthermore, urinary output of NO2-/NO3 was significantly increased.38 Provided the effect of L-arginine involves endogenous NO release, these data suggest that even in hypertensive patients the L-arginine-NO pathway remains operative when suf ficient quantities of the substrate L-arginine are available. The precise mechanisms of L-arginine-induced hypo tension await further investigation.
It has been reported that endothelial cells (cNOS) and smooth muscle cells (iNOS) from genetically hyper tensive rats release less nitric oxide than cells from normotensive animals.39 This result does not necessarily indicate that defective NOS genes are responsible for the hypertension in this model. Alternative explanations include a biochemical defect, such as biosynthesis of a cofactor commonly required for activation of both forms of NOS. Although numerous studies have been published on animal models of hypertension , these studies are not entirely consistent. In fact, they are not strictly compar able, because different vascular preparations from differ ent species stimulated with different agonists were used . There is a need for a more systematic study of the dysfunction, if any, underlying hypertension . NO satisfies several criteria for a neurotransmitter, including occurrence of the synthetic enzyme in the relevant neurons, mimicking by NO of the effects of physiologic nerve stimulation, and blockade of the effects of nerve stimulation after inhibition of NO synthesis. However, NO is an atypical neurotransmitter candidate. Most neurotransmitters are stored in synaptic vesicles, released by fusion with the synaptic membranes. In contrast, electron microscopic immunohistochemistry shows that in myenteric plexus nerve terminals NOS does not occur in synaptic vesicles or in association with the plasma membrane, but rather appears to be largely cytoplasmic. NO is synthesized on demand and diffuses freely out of neurons. In postsynaptic cells its only known receptor or acceptor is the iron in guanylate cyclase. Recent evidence suggests that in addition to iron, a sulfhydryl moiety may be an acceptor of nitrogen monoxide in the nitrosonium cation form. Like other neurotransmitters, NO release depends on Ca2+ influx into nerve terminals. The calcium/calmodulin-dependent enzyme, NOS, is activated by an increase in cytosolic Ca2+. In the gastrointestinal tract, NOS is colocalized with vasoactive intestinal polypeptide. Nitric oxide and cyclic GMP formation in response to electrical field stimulation cause relaxation of corpus cavernosum smooth muscle, suggesting that penile erection may be mediated by NO generated in response to NANC neurotransmission.80 In intact rats, physiologic stimulation of the pelvic nerves leads to penile erection, which is abolished by small doses of NOS inhibitors. 81 NOS is localized to penile neurons innervating the corpora cavernosa and to neuronal plexuses in the adven titial layer of penile arteries. It is likely that in humans, NO is essential for penile erection.82
The nitric oxide donor linsidomine chlorhydrate (SIN 1) was administered to patients with erectile dysfunction . Out of 63 patients, 29 had a full, 21 an almost full and 13 a moderate reaction to 1mg SIN-1.83 play a positive or a negative modulatory role in LTP.91 NMDA receptor stimulation activates nitric oxide synthesis from L-arginine in rat brain slices.92 Purifi cation93 and cloning94 of cerebellar NOS, followed by the use of an antibody to identify cNOS-related antigens in the cerebellum strengthened the view that NO may mediate neuronal responses to excitatory amino acids. A current view is that glutamate released from certain presynaptic neurons elicits a calcium transient in the postsynaptic neuron, activating its NOS. Formed NO in turn diffuses from the postsynaptic neuron in a retrograde manner to reach the presynaptic neuron.
There is no convincing evidence, however, for the existence of NOS in postsynaptic neurons. Instead, it has been shown that astrocytes have cNOS-like activity and iNOS induced by immunological stimuli.95-97 The demonstration of cNOS activity in astrocytes is not con vincing, because potential LPS contamination was not controlled such that the apparent cNOS activity may in fact have been iNOS activity. It is known that contami nation with undefined concentrations of LPS with exper imental systems may induce NOS. 49 In LTD, stimulation of climbing fibers and parallel fibers results in diminished synaptic efficacy of parallel fiber-Purkinje cell synapses. Climbing fiber stimulation releases NO, and NOS inhibitors block LTD. 103 Since cNOS is an NADPH diaphorase, it is possible that cNOS containing neurons kill cNOS-negative cells. This con tention is supported by the ability of an NOS inhibitor to block the neurotoxic actions of glutamate.103 How ever, despite the strong evidence for NO-mediated neurotoxicity,104,105 in some studies it also seems to be neuroprotective. 106 The neuroprotective action may be explained by observations that NO can nitro sylate the NMDA receptor, blocking glutamate neurotransmission. 107 The paradox of NO being both neuroprotective and neurodestructive was resolved by Lipton et al (1993) . It has become clear that the congener of nitrogen monoxide, NO, should be taken into account . NO' -mediated neurotoxicity is generated , in part, by reaction with superoxide anion (O2'-) , apparently leading to formation of peroxynitrite (ONOO-) , and not by NO' Allergic encephalitis
Both infection with one of several viruses known to cause neural pathology and induction of experimental allergic encephalitis can cause the appearance of patho logical change and also the induction of NOS.114 Ident ified sources of iNOS in the brain include astrocytes and microglia. 97, 115 NO may be responsible, in part, for encephalitis in patients with acquired immunodeficiency syndrome (AIDS). The neural toxicity caused by the coat protein to human immunodeficiency virus type 1 (HIV-1), the infectious agent in AIDS, may be mediated through NO. 116 The coat protein gp120 of HIV-1 exerts an agonistic action on the glutamate receptor, which is well known to generate NO and to cause neuronal death. Small heat-stable toxins secreted by HIV infected mono nuclear phagocytes also appear to act via NMDA receptors.117
Convulsion
Cyclic GMP has long been suggested to play a role in seizures and the cyclic GMP levels increased in several brain regions before the onset of seizures.118 Excitatory amino acid-mediated convulsant activity may occur through the subsequent activation of NOS. Thus, intra cerebroventricular injections of exogenous L-arginine induced behavioral and electroencephalographic activation.119 L-Arginine also produces proconvulsant effects in rats treated with subconvulsive doses of NMDA, and these effects are prevented by an NOS inhibitor. Harmaline-induced tremor may involve NO, since harmaline administration to rats activates climbing fibers within the cerebellum, releasing glutamate with the subsequent formation of NO. 120,121
Pancreatic Islet Function
Antibody to constitutive NOS stains islet B cells122 and the substrate of NOS, L-arginine, stimulates insulin release from the islets.123 This raises the possibility that, in diabetes mellitus, the L-arginine-NO pathway is im paired. However, the issue is not straightforward, since at a lower concentration NO plays a regulatory role and excessive NO apparently impairs islet functions.
Islet cell death during the development of Type 1 (insulin-dependent) diabetes mellitus has been thought to be mediated in part by oxygen radicals and interleukin 1. Cytokines induce iNOS in islets and inhibit insulin release in vitro. 124 Recent evidence indicates that interleukin-1-induced islet cell lysis is completely abol ished when NO synthesis has been prevented. 125 The induction of diabetes mellitus by administration of strep tozotocin to animals seems to be associated with pro duction of islet iNOS. The administration of an NOS inhibitor diminished both insulitis and hyperglycemia. 126 An NO donor, nitroprusside, was shown to be cytotoxic against a murine beta-cell line. 127 The sources of iNOS in islets include macrophages and endothelium. We can speculate as to the mechanism of NO cytotoxicity in islets: nitric oxide, which is induced by interleukin 1 and other stimuli, reacts with oxygen radicals, resulting in the formation of a highly toxic compound, peroxynitrite.
Impaired endothelium-dependent relaxation has been observed in blood vessels of genetically diabetic rats. 128 Nitroglycerin, an NO-producing drug, was used for the treatment of angina pectoris long before the discovery of endogenous nitric oxide. There are a number of such instances, in which a compound was in clinical use long before its corresponding endogenous substance was identified. Morphine, and atropine, for example, were in widespread use before their respective endogenous sub stance, opioid peptides and acetylcholine, were known. In contrast to these substances, however, the discovery of nitric oxide prompted several clinical trials with nitric oxide-related compounds in human subjects. In light of the numerous physiological functions of nitric oxide, it is clear that not only nitric oxide generators, but also inhibitors of NO synthase and modifiers of redox state of nitrogen monoxide, potentially have broad clinical appli cations. Further understanding of the physiology and pathophysiology of nitric oxide will undoubtedly open new therapeutic horizons. 
